Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 95705 | 3.52 |
09:34 ET | 22332 | 3.525 |
09:36 ET | 31133 | 3.545 |
09:38 ET | 40734 | 3.58 |
09:39 ET | 41858 | 3.595 |
09:41 ET | 20460 | 3.61 |
09:43 ET | 10723 | 3.625 |
09:45 ET | 47099 | 3.615 |
09:48 ET | 30976 | 3.625 |
09:50 ET | 22258 | 3.62 |
09:52 ET | 39158 | 3.64 |
09:54 ET | 95606 | 3.65 |
09:56 ET | 28310 | 3.645 |
09:57 ET | 87306 | 3.615 |
09:59 ET | 110741 | 3.625 |
10:01 ET | 24520 | 3.635 |
10:03 ET | 39223 | 3.6399 |
10:06 ET | 26017 | 3.6098 |
10:08 ET | 36222 | 3.61 |
10:10 ET | 81346 | 3.61 |
10:12 ET | 52957 | 3.605 |
10:14 ET | 38831 | 3.58 |
10:15 ET | 26309 | 3.565 |
10:17 ET | 34002 | 3.58 |
10:19 ET | 69256 | 3.595 |
10:21 ET | 175859 | 3.585 |
10:24 ET | 27626 | 3.605 |
10:26 ET | 35779 | 3.585 |
10:28 ET | 13084 | 3.56 |
10:30 ET | 10905 | 3.55 |
10:32 ET | 26764 | 3.575 |
10:33 ET | 44939 | 3.575 |
10:35 ET | 2227 | 3.58 |
10:37 ET | 53882 | 3.57 |
10:39 ET | 25325 | 3.5899 |
10:42 ET | 2879 | 3.59 |
10:44 ET | 11995 | 3.585 |
10:46 ET | 17309 | 3.585 |
10:48 ET | 20816 | 3.57 |
10:50 ET | 65549 | 3.555 |
10:51 ET | 17763 | 3.55 |
10:53 ET | 41035 | 3.555 |
10:55 ET | 49863 | 3.535 |
10:57 ET | 19637 | 3.545 |
11:00 ET | 21842 | 3.57 |
11:02 ET | 86213 | 3.575 |
11:04 ET | 35958 | 3.56 |
11:06 ET | 7474 | 3.555 |
11:08 ET | 30694 | 3.565 |
11:09 ET | 20194 | 3.555 |
11:11 ET | 10223 | 3.565 |
11:13 ET | 6333 | 3.565 |
11:15 ET | 14531 | 3.56 |
11:18 ET | 5172 | 3.565 |
11:20 ET | 8584 | 3.565 |
11:22 ET | 19532 | 3.555 |
11:24 ET | 7972 | 3.555 |
11:26 ET | 46190 | 3.56 |
11:27 ET | 5644 | 3.56 |
11:29 ET | 19290 | 3.55 |
11:31 ET | 7065 | 3.551 |
11:33 ET | 5119 | 3.555 |
11:36 ET | 81882 | 3.55 |
11:38 ET | 13457 | 3.55 |
11:40 ET | 1700 | 3.54 |
11:42 ET | 2403 | 3.545 |
11:44 ET | 3218 | 3.545 |
11:45 ET | 20997 | 3.555 |
11:47 ET | 47119 | 3.5861 |
11:49 ET | 18422 | 3.59 |
11:51 ET | 58662 | 3.585 |
11:54 ET | 14002 | 3.585 |
11:56 ET | 36743 | 3.585 |
11:58 ET | 1736 | 3.59 |
12:00 ET | 12360 | 3.585 |
12:02 ET | 29187 | 3.57 |
12:03 ET | 5259 | 3.575 |
12:05 ET | 21081 | 3.57 |
12:07 ET | 2899 | 3.57 |
12:09 ET | 3099 | 3.57 |
12:12 ET | 51969 | 3.56 |
12:14 ET | 39327 | 3.55 |
12:16 ET | 23300 | 3.545 |
12:18 ET | 35737 | 3.555 |
12:20 ET | 54507 | 3.55 |
12:21 ET | 69930 | 3.55 |
12:23 ET | 57113 | 3.555 |
12:25 ET | 8362 | 3.555 |
12:27 ET | 2284 | 3.55 |
12:30 ET | 5066 | 3.55 |
12:32 ET | 5940 | 3.555 |
12:34 ET | 5246 | 3.56 |
12:36 ET | 4846 | 3.55 |
12:38 ET | 40743 | 3.555 |
12:39 ET | 3192 | 3.55 |
12:41 ET | 2861 | 3.555 |
12:43 ET | 4930 | 3.55 |
12:45 ET | 18569 | 3.555 |
12:48 ET | 16454 | 3.555 |
12:50 ET | 1800 | 3.55 |
12:52 ET | 5539 | 3.55 |
12:54 ET | 3725 | 3.555 |
12:56 ET | 28169 | 3.565 |
12:57 ET | 28774 | 3.58 |
12:59 ET | 20658 | 3.585 |
01:01 ET | 778 | 3.59 |
01:03 ET | 4678 | 3.585 |
01:06 ET | 7426 | 3.585 |
01:08 ET | 13678 | 3.595 |
01:10 ET | 72481 | 3.575 |
01:12 ET | 26328 | 3.56 |
01:14 ET | 19220 | 3.56 |
01:15 ET | 3319 | 3.565 |
01:17 ET | 21008 | 3.555 |
01:19 ET | 28874 | 3.555 |
01:21 ET | 2376 | 3.56 |
01:24 ET | 10168 | 3.56 |
01:26 ET | 4585 | 3.56 |
01:28 ET | 6169 | 3.555 |
01:30 ET | 2717 | 3.555 |
01:32 ET | 51389 | 3.55 |
01:33 ET | 47030 | 3.55 |
01:35 ET | 4644 | 3.545 |
01:37 ET | 6017 | 3.545 |
01:39 ET | 6647 | 3.545 |
01:42 ET | 24524 | 3.55 |
01:44 ET | 8121 | 3.545 |
01:46 ET | 7001 | 3.55 |
01:48 ET | 20337 | 3.55 |
01:50 ET | 93817 | 3.54 |
01:51 ET | 3900 | 3.55 |
01:53 ET | 6264 | 3.55 |
01:55 ET | 8695 | 3.55 |
01:57 ET | 7140 | 3.545 |
02:00 ET | 5227 | 3.545 |
02:02 ET | 65648 | 3.545 |
02:04 ET | 10527 | 3.55 |
02:06 ET | 1989 | 3.545 |
02:08 ET | 44113 | 3.55 |
02:09 ET | 82206 | 3.55 |
02:11 ET | 6426 | 3.555 |
02:13 ET | 2550 | 3.55 |
02:15 ET | 8560 | 3.56 |
02:18 ET | 14747 | 3.55 |
02:20 ET | 3222 | 3.555 |
02:22 ET | 28498 | 3.545 |
02:24 ET | 20896 | 3.545 |
02:26 ET | 4426 | 3.54 |
02:27 ET | 6936 | 3.54 |
02:29 ET | 2800 | 3.545 |
02:31 ET | 31056 | 3.535 |
02:33 ET | 6809 | 3.53 |
02:36 ET | 3400 | 3.53 |
02:38 ET | 12459 | 3.535 |
02:40 ET | 9403 | 3.535 |
02:42 ET | 6440 | 3.535 |
02:44 ET | 11462 | 3.535 |
02:45 ET | 10893 | 3.535 |
02:47 ET | 83196 | 3.53 |
02:49 ET | 11478 | 3.53 |
02:51 ET | 35634 | 3.535 |
02:54 ET | 7514 | 3.535 |
02:56 ET | 5908 | 3.535 |
02:58 ET | 3213 | 3.53 |
03:00 ET | 6938 | 3.535 |
03:02 ET | 9099 | 3.535 |
03:03 ET | 55862 | 3.525 |
03:05 ET | 4943 | 3.53 |
03:07 ET | 16345 | 3.52 |
03:09 ET | 4412 | 3.525 |
03:12 ET | 6782 | 3.52 |
03:14 ET | 8800 | 3.525 |
03:16 ET | 7359 | 3.52 |
03:18 ET | 5300 | 3.525 |
03:20 ET | 48379 | 3.515 |
03:21 ET | 10886 | 3.515 |
03:23 ET | 12913 | 3.52 |
03:25 ET | 11626 | 3.5112 |
03:27 ET | 9996 | 3.51 |
03:30 ET | 241828 | 3.525 |
03:32 ET | 20090 | 3.525 |
03:34 ET | 5066 | 3.5279 |
03:36 ET | 84875 | 3.535 |
03:38 ET | 4279 | 3.535 |
03:39 ET | 5503 | 3.535 |
03:41 ET | 6214 | 3.535 |
03:43 ET | 62410 | 3.545 |
03:45 ET | 47284 | 3.535 |
03:48 ET | 36257 | 3.535 |
03:50 ET | 59529 | 3.525 |
03:52 ET | 131256 | 3.53 |
03:54 ET | 84444 | 3.55 |
03:56 ET | 82570 | 3.545 |
03:57 ET | 156121 | 3.53 |
03:59 ET | 265579 | 3.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.1B | -10.2x | --- |
Vera Therapeutics Inc | 2.0B | -18.6x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.4x | --- |
Celldex Therapeutics Inc | 2.2B | -11.7x | --- |
CG Oncology Inc | 2.3B | -28.9x | --- |
Agios Pharmaceuticals Inc | 2.1B | -5.8x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.2x |
Price/Sales (TTM) | 3,958.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.